Identification of multiple dense LDL subfractions with enhanced susceptibility to in vitro oxidation among hypertriglyceridemic subjects. Normalization after clofibrate treatment
- PMID: 8485123
- DOI: 10.1161/01.atv.13.5.712
Identification of multiple dense LDL subfractions with enhanced susceptibility to in vitro oxidation among hypertriglyceridemic subjects. Normalization after clofibrate treatment
Abstract
The influence of different plasma triglyceride concentrations on the heterogeneity of low density lipoprotein (LDL) and on the susceptibility of LDL to copper oxidation was investigated. By density gradient ultracentrifugation, LDL subfractions were isolated from the plasma of 10 normolipidemic control subjects and 12 hypertriglyceridemic patients both before and after clofibrate treatment. In the plasma of control subjects three LDL subfractions were present: LDL1 (d = 1.030-1.033 g/mL), LDL2 (d = 1.033-1.040 g/mL), and LDL3 (d = 1.040-1.045 g/mL). In the plasma of nine moderately hypertriglyceridemic subjects up to five LDL subfractions could be detected: LDL1-LDL3, LDL4 (d = 1.045-1.049 g/mL), and LDL5 (d = 1.049-1.054 g/mL). This polydispersity of LDL was replaced by monodispersity with increasing plasma triglyceride concentrations in three subjects with chylomicronemia, in whom LDL was concentrated in the narrow LDL5 density range. Clofibrate treatment resulted in a lighter LDL subfraction pattern (LDL1-LDL4). In both the control and the moderately hypertriglyceridemic subjects, the small dense LDL subfractions appeared more prone to oxidative modification in vitro than the light LDL subfractions, as measured by the decreased lag time preceding the onset of lipid peroxidation. Furthermore, the dense LDL subfractions were more extensively modified over time, as shown by an increased oxidation rate and a greater number of dienes formed after 6 hours of oxidation. These results suggest an enhanced atherogenic potential of the small, dense LDL subfractions within each LDL subfraction profile. The hypertriglyceridemic LDL subfractions before therapy (LDL3-LDL5) were less resistant to in vitro oxidation than the light, control LDL subfractions (LDL1-LDL3).(ABSTRACT TRUNCATED AT 250 WORDS)
Similar articles
-
The effect of concentrated n-3 fatty acids versus gemfibrozil on plasma lipoproteins, low density lipoprotein heterogeneity and oxidizability in patients with hypertriglyceridemia.Atherosclerosis. 2000 Nov;153(1):129-38. doi: 10.1016/s0021-9150(00)00381-6. Atherosclerosis. 2000. PMID: 11058707 Clinical Trial.
-
Oxidizability of atherogenic low-density lipoprotein subspecies in severe familial hypercholesterolemia: impact of long-term low-density lipoprotein apheresis.J Cardiovasc Pharmacol Ther. 2000 Apr;5(2):87-103. doi: 10.1053/XV.2000.5588. J Cardiovasc Pharmacol Ther. 2000. PMID: 11150388 Clinical Trial.
-
Enhanced susceptibility to in vitro oxidation of the dense low density lipoprotein subfraction in healthy subjects.Arterioscler Thromb. 1991 Mar-Apr;11(2):298-306. doi: 10.1161/01.atv.11.2.298. Arterioscler Thromb. 1991. PMID: 1998647
-
Increased activity of platelet-activating factor acetylhydrolase in low-density lipoprotein subfractions induces enhanced lysophosphatidylcholine production during oxidation in patients with heterozygous familial hypercholesterolaemia.Eur J Clin Invest. 1997 Jul;27(7):595-602. doi: 10.1046/j.1365-2362.1997.1570706.x. Eur J Clin Invest. 1997. PMID: 9263748
-
Pharmacological control of hypertriglyceridemia.Cardiovasc Drugs Ther. 1993 Jun;7(3):297-302. doi: 10.1007/BF00880152. Cardiovasc Drugs Ther. 1993. PMID: 8364001 Review.
Cited by
-
The role of fibric acid derivatives in the secondary prevention of coronary heart disease.Curr Cardiol Rep. 2000 Sep;2(5):452-8. doi: 10.1007/s11886-000-0060-z. Curr Cardiol Rep. 2000. PMID: 10980914 Review.
-
Efficacy of Pemafibrate Versus Fenofibrate Administration on Serum Lipid Levels in Patients with Dyslipidemia: Network Meta-Analysis and Systematic Review.Am J Cardiovasc Drugs. 2023 Sep;23(5):547-558. doi: 10.1007/s40256-023-00593-6. Epub 2023 Jul 31. Am J Cardiovasc Drugs. 2023. PMID: 37524955
-
Beyond LDL-C: unravelling the residual atherosclerotic cardiovascular disease risk landscape-focus on hypertriglyceridaemia.Front Cardiovasc Med. 2024 Aug 7;11:1389106. doi: 10.3389/fcvm.2024.1389106. eCollection 2024. Front Cardiovasc Med. 2024. PMID: 39171323 Free PMC article. Review.
-
Postprandial lipemia and coronary risk.Curr Atheroscler Rep. 2000 May;2(3):232-42. doi: 10.1007/s11883-000-0025-0. Curr Atheroscler Rep. 2000. PMID: 11122749 Review.
-
A common genetic mechanism determines plasma apolipoprotein B levels and dense LDL subfraction distribution in familial combined hyperlipidemia.Am J Hum Genet. 1998 Aug;63(2):586-94. doi: 10.1086/301962. Am J Hum Genet. 1998. PMID: 9683593 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical